Perfusion Medical, Inc.
CT
- UEI
- XEDJGXP1K889
- CAGE
- 8MYE9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- Connecticut, USA
- Website
- perfusionmedical.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| IND-enabling studies of PM-208: a novel pre-hospital anti-shock therapeutic | Defense Health Agency | $1,499,773 | |
| Human clinical trial for safety of PM-208 anti-shock drug | Air Force Research Laboratory | $1,799,970 | |
| Polyethylene glycol-20K/8K (peg-20K/8K): a patented intravenous solution in uncontrolled hemorrhage | Air Force Research Laboratory | $109,917 | |
| Research and development of optimal dosing and formulation of PM-208 (peg-20K/8K) for AF field use | Air Force Research Laboratory | $1,799,322 | |
| Polyethylene glycol-20K/8K: a patented intravenous solution to acute kidney injury | Air Force Research Laboratory | $74,975 |
About Perfusion Medical, Inc.
Perfusion Medical, Inc., a small biotechnology company based in Connecticut, develops innovative intravenous therapeutics for acute medical emergencies and serves the federal government exclusively as a prime contractor under total small business set-asides, with no subcontract footprint across its nine recent federal awards.
Perfusion Medical's core capability is the research, development, and clinical advancement of PEG-20K/8K (polyethylene glycol-based formulation), a novel patented intravenous solution designed to treat septic shock, hemorrhagic shock, and acute kidney injury in pre-hospital and field settings. The company commercializes a technology originally developed at Virginia Commonwealth University and collaborates with Mayo Clinic and Virginia Commonwealth University on clinical validation and dosing optimization. Federal work centers on IND-enabling studies, human clinical trials for safety assessment, optimal dosing and formulation refinement, and mechanistic research into tissue perfusion preservation during sepsis. Representative work includes a $2.99 million Defense Health Agency SBIR Phase II contract (awarded September 2023, completing July 2026) for IND-enabling studies of PM-208; two Air Force Research Laboratory STTR Phase II purchase orders totaling $3.6 million (one awarded February 2024, completing April 2026; a second awarded June 2024, completing January 2027) for human clinical trials and optimal dosing research; a $1.5 million Defense Health Agency definitive contract (awarded April 2026, completing August 2027) for IND-enabling studies; and a $275,000 National Institute of General Medical Sciences R41 grant (awarded September 2021, completed December 2022) for polymer-based tissue perfusion research. Herndon, Virginia, is the primary place of performance.
Customer concentration splits between two federal agencies. The Defense Health Agency accounts for two awards valued at $4.5 million in combined potential value, anchoring the dollar base. The Air Force Research Laboratory dominates award volume with six contracts valued at $3.9 million combined potential value, spanning STTR Phase I and Phase II work and SBIR Phase I research. The National Institute of General Medical Sciences contributed one grant award. All work is designated total small business set-aside; Perfusion Medical competes exclusively under small business protections across its federal footprint.
Activity has been episodic. The source records one award in 2021, a gap in 2022, four awards in 2023, three in 2024, and one in 2026. Two awards totaling $3.3 million in combined potential value face completion within the next twenty-four months and will enter recompete. The combined potential value of $8.4 million across nine awards reflects the early-stage biotechnology and clinical development profile typical of SBIR and STTR portfolios; obligated dollars ($9.2 million) have exceeded the stated potential-value ceiling, indicating cost growth or scope adjustments during performance.
Quick answers
What is Perfusion Medical, Inc.'s UEI?
Perfusion Medical, Inc.'s Unique Entity ID (UEI) in SAM.gov is XEDJGXP1K889.
What is Perfusion Medical, Inc.'s CAGE code?
Perfusion Medical, Inc.'s CAGE code is 8MYE9.
What is Perfusion Medical, Inc.'s primary NAICS code?
Perfusion Medical, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Perfusion Medical, Inc. located?
Perfusion Medical, Inc.'s physical address in SAM.gov is Connecticut, USA.
Is Perfusion Medical, Inc. registered in SAM.gov?
Yes. Perfusion Medical, Inc.'s SAM.gov registration is active through June 5, 2027.
What is Perfusion Medical, Inc.'s most recent federal award?
Perfusion Medical, Inc.'s most recent federal contract award is IND-enabling studies of PM-208: a novel pre-hospital anti-shock therapeutic (HT942726CE025), from Defense Health Agency, on April 10, 2026.
On GovTribe
See Perfusion Medical, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors